VEGFR3/Flt-4 Polyclonal Antibody (CAB24866)
- SKU:
- CAB24866
- Product Type:
- Antibody
- Antibody Type:
- Polyclonal Antibody
- Reactivity:
- Human
- Rat
- Host Species:
- Rabbit
- Isotype:
- IgG
- Applications:
- IF
Description
Product Name: | VEGFR3/Flt-4 Polyclonal Antibody |
SKU: | CAB24866 |
Size: | 20uL, 100uL |
Isotype: | IgG |
Host Species: | Rabbit |
Reactivity: | Human,Rat |
Immunogen: | Recombinant fusion protein containing a sequence corresponding to amino acids 25-229 of mouse VEGFR3/Flt-4(NP_032055.1). |
Sequence: | YSMT PPTL NITE DSYV IDTG DSLS ISCR GQHP LEWT WPGA QEVL TTGG KDSE DTRV VHDC EGTE ARPY CKVL LLAQ THAN NTGS YHCY YKYI KARI EGTT AAST YVFV RDFK HPFI NKPD TLLV NRKD SMWV PCLV SIPG LNIT LRSQ SSAL HPDG QEVL WDDR RGMR VPTQ LLRD ALYL QCET TWGD QNFL SNLF VVHI TGNE L |
Tested Applications: | IF/ICC |
Recommended Dilution: | IF/ICC,1:50 - 1:200 |
Synonyms: | flt 4; FLT-4; VEGF R3; VEGFR 3; VEGFR-3; FLT4; LMPH1A; PCL; Vegfr3; VEGFR3/Flt-4 |
Conjugate: | Unconjugated |
Cellular Localization: | Cell membrane, Cytoplasm, Nucleus |
Calculated MW: | 153kDa |
Observed MW: | Refer to figures |
Defects in FLT4 are the cause of lymphedema hereditary type 1A (LMPH1A) [MIM:153100]; also known as Nonne-Milroy lymphedema or Milroy disease. Hereditary lymphedema is a chronic disabling condition which results in swelling of the extremities due to altered lymphatic flow. Patients with lymphedema suffer from recurrent local infections and physical impairment._x000D_ Note=Defects in FLT4 are found in juvenile hemangioma. Juvenile hemangiomas are the most common tumors of infancy, occurring as many as 10% of all births. These benign vascular lesions enlarge rapidly during the first year of life by hyperplasia of endothelial cells and attendant pericytes, and then spontaneously involute over a period of years, leaving loose fibrofatty tissue.
Purification Method: | Affinity purification |
Gene ID: | 14257 |
Storage Buffer: | Store at -20℃. Avoid freeze / thaw cycles.Buffer: PBS with 0.05% proclin300,50% glycerol,pH7.3. |